(Q34246891)

English

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

chronic heart failure

1 reference

based on heuristic

inferred from title

Christopher B. Granger

4

object named as

Christopher B Granger

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

3

object named as

Karl Swedberg

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

8

object named as

Salim Yusuf

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1

object named as

John J V McMurray

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

9

object named as

Marc A Pfeffer

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

CHARM Investigators and Committees

10

object named as

CHARM Investigators and Committees

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Eric L Michelson

6

object named as

Eric L Michelson

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

5

object named as

Peter Held

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Jan Ostergren

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Bertil Olofsson

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

362

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

9386

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

767-771

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Angiotensin II-forming pathways in normal and failing human hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional and biochemical analysis of angiotensin II-forming pathways in the human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) pro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Heart failure therapy at a crossroad: are there limits to the neurohormonal model?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in hospitalization for heart failure in Scotland, 1990–1996. An epidemic that has reached its peak?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The current cost of heart failure to the National Health Service in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914283-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(03)14283-3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34246891&oldid=1744703950"